Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

NNC0165-1875

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Novo Nordisk · Phase 2 · Completed · Enrollment 120

NCT04969939

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Semaglutide 2.4 mg and NNC0165-1875 2.0 mgn/rn/rn/rn/rn/r
Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)n/rn/rn/rn/rn/r
Semaglutide 2.4 mg and NNC0165-1875 1.0 mgn/rn/rn/rn/rn/r
Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)n/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.